Bayer says eye drug meets goal in diabetic macular edema trials

FRANKFURT Tue Aug 6, 2013 7:46am BST

Related Topics

Quotes

   

FRANKFURT Aug 6 (Reuters) - Bayer said on Tuesday that two late-stage studies testing its drug VEGF Trap-Eye against diabetic macular edema (DME) met their primary goals.

Bayer co-develops the eye drug, also known as Eylea, with Regeneron.

Bayer said that Regeneron now expects to submit an application for U.S. marketing approval for the treatment of DME in 2013, about a year earlier that previously planned.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.